How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Benign Prostatic Hyperplasia Device Market
- By Product Type: Transurethral Resection of the Prostate (TURP) Devices, Laser Therapy Devices, Prostatic Urethral Lift (PUL) Devices, Water Vapor Thermal Therapy Devices, Microwave Therapy Devices
- By Technology: Laser Technology, Radiofrequency Technology, Microwave Technology, Water Vapor Thermal Technology, Mechanical Urethral Lift Technology
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Urology Clinics
- By Procedure Type: Minimally Invasive Procedures, Surgical Procedures
Top segment
Transurethral Resection of the Prostate (TURP) Devices XX% share · $X,XXXM
In the full report →
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Transurethral Resection of the Prostate (TURP) Devices leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.163 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.171 →
Full report · locked preview
Everything inside the Benign Prostatic Hyperplasia Device Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Technology 5
End User 4
Procedure Type 2
Companies profiled
Boston Scientific Corporation
C.R. Bard (now part of BD)
Olympus Corporation
Richard Wolf GmbH
UroLift (Teleflex Incorporated)
Sonacare Medical LLC
SonaCare Medical
Medi-Tate Inc.
Minerva Surgical Inc.
Quanta System S.p.A.
EDAP TMS S.A.
Cook Medical
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →C.R. Bard (now part of BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Olympus Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Richard Wolf GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →UroLift (Teleflex Incorporated)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sonacare Medical LLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →SonaCare Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Medi-Tate Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Minerva Surgical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Quanta System S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →EDAP TMS S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cook Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Biosense Webster (Johnson & Johnson)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Medtronic
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,910M by 2033 · 10.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Transurethral Resection of the Prostate (TURP) Devices52.2
- Laser Therapy Devices13.9
- Prostatic Urethral Lift (PUL) Devices7.7
- Water Vapor Thermal Therapy Devices9.9
- Microwave Therapy Devices16.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$598.5M → $1,415M · 11.4%
Europe$417.2M → $958.7M · 11.0%
Asia Pacific$380.9M → $835.6M · 10.3%
Latin America$235.8M → $471.3M · 9.0%
Middle East and Africa$181.4M → $359.1M · 8.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.042026
10.042027
10.052028
10.062029
10.082030
10.092031
10.102032
10.112033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boston Scientific Corporation11.8
- C.R. Bard (now part of BD)23.7
- Olympus Corporation11.5
- Richard Wolf GmbH5.7
- UroLift (Teleflex Incorporated)6.0
- Sonacare Medical LLC13.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type17.4%
Technology17.3%
End User44.3%
Procedure Type21.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.0
- Europe23.7
- Asia Pacific20.7
- Latin America11.7
- Middle East and Africa8.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 95 | 91 | 98 | 84 | 77 | 94 | 90 |
| C.R. Bard (now part of BD) | 74 | 90 | 73 | 89 | 82 | 68 | 79 |
| Olympus Corporation | 67 | 77 | 71 | 82 | 70 | 66 | 72 |
| Richard Wolf GmbH | 81 | 73 | 78 | 69 | 58 | 62 | 70 |
| UroLift (Teleflex Incorporated) | 68 | 65 | 60 | 70 | 60 | 61 | 64 |
| Sonacare Medical LLC | 55 | 69 | 70 | 49 | 56 | 51 | 58 |
| SonaCare Medical | 49 | 45 | 62 | 53 | 66 | 63 | 56 |
| Medi-Tate Inc. | 43 | 56 | 52 | 45 | 53 | 60 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boston Scientific Corporation
- C.R. Bard (now part of BD)
- Olympus Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| C.R. Bard (now part of BD) | ✓ | ✓ | − | ✓ | ✓ | ◐ |
| Olympus Corporation | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Richard Wolf GmbH | ◐ | − | ✓ | ◐ | − | ◐ |
| UroLift (Teleflex Incorporated) | ✓ | − | ◐ | ◐ | ◐ | ✓ |
| Sonacare Medical LLC | ◐ | ◐ | ✓ | − | ◐ | − |
| SonaCare Medical | ◐ | − | ✓ | ◐ | ◐ | ◐ |
| Medi-Tate Inc. | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Boston Scientific Corporation90
2C.R. Bard (now part of BD)79
3Olympus Corporation72
4Richard Wolf GmbH70
5UroLift (Teleflex Incorporated)64
6Sonacare Medical LLC58
7SonaCare Medical56
8Medi-Tate Inc.52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Boston Scientific CorporationC.R. Bard (now part of BD)
Challenger2
Strong scale, closing on the leaders.
Olympus CorporationRichard Wolf GmbH
Contender2
Focused players with pockets of strength.
UroLift (Teleflex Incorporated)Sonacare Medical LLC
Niche2
Specialists in a single segment or region.
SonaCare MedicalMedi-Tate Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Benign Prostatic Hyperplasia Device Market — a $380M beachhead inside a $6.68B market.
Beachhead (SOM)$380Mobtainable near-term
Serviceable (SAM)$2.31Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Transurethral Resection of the Prostate (TURP) Devices
Best fit — highest urgency & budget in Product Type.
Economic buyer80 fit
Laser Therapy Devices
Strong fit — clear ROI and a fast path to value.
End user69 fit
Prostatic Urethral Lift (PUL) Devices
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel29%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Benign Prostatic Hyperplasia Device Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified24%
Evaluation13%
Closed-won6%
$17.7KCAC
$90KLTV
5.1:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Benign Prostatic Hyperplasia Device Market is a durable-growth opportunity — $11.0B by 2033, compounding at 9.3%.
TAM · 2025$5.42Btoday
TAM · 2033$11.0Bforecast
CAGR9.3%2027–2033
Cumulative$71.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$11.0BTotal addressable market
SAM$4.23BServiceable available market
SOM$847MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$11.0BLarge & growingTAM by 2033 at 9.3% CAGR
$4.23BServiceable nowreachable with today’s model
$847MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.59BBear6.0% CAGR
$11.0BBase9.3% CAGR
$14.1BBull12.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Benign Prostatic Hyperplasia Device Market — a $4.36B market by 2033. Plan: grow share from 9.9% to 15.4%.
Market size · 2033$4.36Btotal addressable
Market CAGR10.2%2027–2033
Target share15.4%from 9.9% today
Revenue ambition$671Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.9% | 15.4% | On track |
| Revenue | $458M | $671M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 33.2% | 38.0% | Ahead |
| Customer retention | 85.5% | 93.1% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $91M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Benign Prostatic Hyperplasia Device Market conversation — a $6.91B market you can size, segment and defend in minutes.
Market size · 2033$6.91Btotal opportunity
Growth10.5%CAGR to 2033
Addressable buyers1,122+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 4 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Boston Scientific CorporationC.R. Bard (now part of BD)Olympus CorporationRichard Wolf GmbHUroLift (Teleflex Incorporated)Sonacare Medical LLCSonaCare MedicalMedi-Tate Inc.+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Benign Prostatic Hyperplasia Device Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Benign Prostatic Hyperplasia Device Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Benign Prostatic Hyperplasia Drug Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportBenign Prostatic Hyperplasia Treatment Device Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportBenkelman Beam Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportBenlysta Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportBenoxaprofen Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportBenperidol Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBenproperine (CAS 2156-27-6) Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportBenproperine Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBenserazide hydrochloride CAS 14919-77-8 Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportBenserazide Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBentable Cold Drawn Steel Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportBentch-top Veterinary Hematology Analyzers Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.